Evidence map›Paper›PMID 35668219›Full record

ReviewNature reviews. Endocrinology2022

The burden and risks of emerging complications of diabetes mellitus.

Dunya Tomic, Jonathan E Shaw, Dianna J Magliano

2 registry-linked trialsAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Nature reviews. Endocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 511 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
511citing papers in PubMed, 6 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06759922 phase4completedstarted 2025, after this paper: background citation

Clinical Efficacy and Safety of Glimepiride, Empagliflozin and Sitagliptin With Metformin in Type 2 Diabetes Mellitus: A Double and Triple Drug Therapy

Ran2025Enrolled172Registered outcomes2Posted comparisons0ConditionsType 2 Diabetes MellitusArmsTab Metformin + Tab Empagliflozin, Tab Metformin + Tab Empagliflozin + Tab Sitagliptin, Tab Metformin + Tab Glimepiride, Tab Metformin +Tab Sitagliptin
PMID 34388848PMID 31081587PMID 30961501PMID 32041141PMID 32690918PMID 33736819PMID 34352984PMID 34385345PMID 35309368PMID 36151309PMID 36507650PMID 37809225other papers from this trial
Open the trial in the graph
NCT07252700 narecruitingnot on this mapstarted 2025, after this paper: background citation

Preventing Diabetes: Impact of an EMR-Based Intervention for Enhanced Pre-Diabetes Management in Primary Care

TypeinterventionalSponsorLynette GohRan2025 to 2028Enrolled6,000ConditionsPre Diabetes, Diabetes (DM)ArmsElectronic Medical Record-Based Clinical Decision Support
3 · Its place in the literature

Who cites it

511 citing papers in PubMed, 6 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Article
  14. Investigation of Bio-Functional Properties of ZrOApplied biochemistry and biotechnology · 2026
    Article
  15. Article
  16. Investigating the Antidiabetic Effects ofFood science & nutrition · 2026
    Article
  17. Article
  18. Article
  19. Article
  20. Article

451 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Dunya TomicBaker Heart and Diabetes Institute, Melbourne, Victoria, Australia.ORCID http://orcid.org/0000-0003-2471-2523
Jonathan E ShawBaker Heart and Diabetes Institute, Melbourne, Victoria, Australia.ORCID http://orcid.org/0000-0002-6187-2203
Dianna J MaglianoBaker Heart and Diabetes Institute, Melbourne, Victoria, Australia. Dianna.Magliano@baker.edu.au.ORCID http://orcid.org/0000-0002-9507-6096

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The traditional complications of diabetes mellitus are well known and continue to pose a considerable burden on millions of people living with diabetes mellitus. However, advances in the management of diabetes mellitus and, consequently, longer life expectancies, have resulted in the emergence of evidence of the existence of a different set of lesser-acknowledged diabetes mellitus complications. With declining mortality from vascular disease, which once accounted for more than 50% of deaths amongst people with diabetes mellitus, cancer and dementia now comprise the leading causes of death in people with diabetes mellitus in some countries or regions. Additionally, studies have demonstrated notable links between diabetes mellitus and a broad range of comorbidities, including cognitive decline, functional disability, affective disorders, obstructive sleep apnoea and liver disease, and have refined our understanding of the association between diabetes mellitus and infection. However, no published review currently synthesizes this evidence to provide an in-depth discussion of the burden and risks of these emerging complications. This Review summarizes information from systematic reviews and major cohort studies regarding emerging complications of type 1 and type 2 diabetes mellitus to identify and quantify associations, highlight gaps and discrepancies in the evidence, and consider implications for the future management of diabetes mellitus.

Indexed as

Cost of IllnessDiabetes Mellitus, Type 2ComorbidityHumansRisk

Identifiers

PMID35668219
PMCPMC9169030

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.